Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018991 (hemiplegia)
 3,997 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A total of 191 patients with hemispheric lesion mainly due to CVD were examined by the finger-tapping test, and their disturbances of rhythm formation, 'hastening phenomenon' (HP), were compared with those of Parkinson's disease. HP was observed in 56% of the right and 49% of the left hemiplegic patients. HP in the intact hand of the patient was highly correlated with that of the affected hand. CT scans were examined in 86 of 191 patients, and HP was specifically correlated with unilateral striatal lesions. Thus, the disturbances of rhythm formation in hemiplegia, together with those in Parkinson's disease, Huntington's chorea, SND and OPCA, were attributed either to organic or functional deficits in the striatum.
 ...
PMID:Disturbances of rhythm formation in patients with hemispheric lesion. 731 11

The authors provide an extensive review of new data related to the role of glutamate in CNS disorders, describing new aspects in glutamate and glutamatergic receptors-NMDA receptors, NR2B-selective antagonists, non-NMDA ionotropic glutamate receptors, N-acetylaspartylglutamate, and glutamate and glycine transporters. New findings in animal models and in human diseases-stroke, traumatic brain injury, Alzheimer's, Parkinson's and Huntington's diseases, tardive dyskinesia, ALS, olivopontcerebellar degeneration, AIDS, allergic encephalomyelitis, epilepsy, anxiety, depression, schizophrenia, liver disease, aminoglycoside antibiotic-induced hearing loss, hemiplegia, chronic pain and drug tolerance and abuse-are presented. Finally, the authors cite the progress achieved in the development of agents that interact with the glutamatergic system: NMDA channel blockers, competitive NMDA receptor antagonists, NR2B-selective antagonists, glutamate release inhibitors, glycineB antagonists, AMPA and kainate receptor antagonists, AMPA receptor-positive modulators and agents that act by modifying endogenous kynurenic acid metabolism.
 ...
PMID:Glutamate in CNS disorders as a target for drug development: an update. 1561 69